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hhF. Hoffmann-La Roche Ltd., SwitzerlandAbstract Introduction: Quantitative in vivo measurement of brain amyloid burden is important for both
research and clinical purposes. However, the existence of multiple imaging tracers presents
challenges to the interpretation of such measurements. This study presents a direct comparison of
Pittsburgh compound B–based and florbetapir-based amyloid imaging in the same participants
from two independent cohorts using a crossover design.
Methods: Pittsburgh compound B and florbetapir amyloid PET imaging data from three different
cohorts were analyzed using previously established pipelines to obtain global amyloid burden
measurements. These measurements were converted to the Centiloid scale to allow fair comparison
between the two tracers. The mean and inter-individual variability of the two tracers were compared
using multivariate linear models both cross-sectionally and longitudinally.
Results: Global amyloid burden measured using the two tracers were strongly correlated in both
cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer.
The variability may be partially caused by white matter signal as partial volume correction reduces
the variability and improves the correlations between the two tracers. Amyloid burden measured
using both tracers was found to be in association with clinical and psychometric measurements.
Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose
baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was
detected in the average annualized rate of change measurements made with these two tracers.
Discussion: Although the amyloid burden measurements were quite similar using these two tracers
as expected, difference was observable even after conversion into the Centiloid scale. Further
investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired
using different tracers.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: PiB; Florbetapir; Amyloid imaging; Centiloid; Positron emission tomography1. Introduction
Amyloid pathology is a neuropathological hallmark of
Alzheimer’s disease (AD), and it is well established that
this pathology begins to accumulate decades before clinical
symptoms appear [1–7]. Positron emission tomographic
(PET) imaging using amyloid tracers can measure amyloid
pathology in vivo and plays an important role in research,
clinical trials, diagnosis, and monitoring of AD. The first
selective amyloid PET imaging tracer, [11C]-Pittsburgh
compound B (PiB) [8], has been used for over a decade
and generated invaluable data to improve our understanding
of AD; however, owing to its short half-life (20 minutes) as a
11C-labeled radioligand, PiB imaging is limited to large
research centers with an onsite cyclotron. Recently, several
18F-based radioligands, [18F]-florbetapir [9], [18F]-florbeta-
ben [10], [18F]-flutemetamol [11], and [18F]-NAV4694
[12], were developed to enable wide application of amyloid
PET imaging given the longer half-life (110 minutes) of 18F.
The availability of multiple amyloid imaging tracers, in
addition to the heterogeneity in imaging analysis protocols,leads to difficulties in interpreting the amyloid burden
measurements across different groups [13]. To address this
issue, the Centiloid Working Group proposed to establish a
common scale (the Centiloid scale), which is defined based
on two anchor points: the mean amyloid burden of a young
control group presumed to have no amyloid plaque in their
brain (defined as 0 on the Centiloid scale) and the mean
amyloid burden of an AD group (defined as 100 on the
Centiloid scale) [13]. They further outlined the procedure
necessary to convert tracer- and group-dependent outcome
measures of amyloid burden into the Centiloid scale [13].
Following this procedure, the conversion of amyloid burden
measurements using [18F]-NAV4694 and [18F]-florbetaben
to the Centiloid scale have been published [14,15]. More
recently, conversion to the Centiloid scale for
[18F]-florbetapir was also reported, although the
underlying florbetapir data were based on 10-minute scans
rather than commonly adopted 50- to 70-minute time
window [16]. Further investigation is warranted to compare
the different tracers to help investigators making informed
decisions on which tracers to use in their study.
Y. Su et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 180-190182Here, we present a study that directly compares PiB and
florbetapir data in the same participants in cohorts of
autosomal dominant as well as sporadic AD, and we also
compare the two tracers using longitudinal data acquired
on two similar, but separate, cohorts of sporadic AD
spectrum participants. All the comparisons are made using
the Centiloid scale.
2. Methods
2.1. Participants
The data set used in this study came from three different
cohorts. The first cohort examined 182 participants from the
Dominantly Inherited Alzheimer’s Network Trial Unit
(DIAN-TU) [17] (https://clinicaltrials.gov/ct2/show/NCT0
1760005) with baseline amyloid PET imaging data using
both PiB and florbetapir. A total of 194 initial participants
were recruited, but 12 were either missing imaging data or
the processing did not pass quality control. In brief,
enrollment criteria were being at risk for an autosomal
dominant AD (ADAD)mutation, a Clinical Dementia Rating
(CDR) score [18] of 0, 0.5, or 1, and an estimated years to
symptom onset (EYO) of 215 to 110. Among the 182
DIAN-TU participants included in this study, 50 did not
carry ADAD mutations (29 of these 50 participants were
younger than 45), and 132 were mutation carriers (see
Table 1 for more information). To define the Centiloid
conversion equation for florbetapir, we followed the
procedure outlined by the Centiloid Working Group [13]
using a calibration data set randomly selected from the
DIAN-TU cohort including 15 noncarriers younger than 45
and 22 mutation carriers who are 45 years and older with
preclinical (amyloid positive and CDR5 0) or symptomatic
AD (amyloid positive and CDR . 0). Amyloid positivity
was defined based on PiB imaging results using previously
determined thresholds (mean cortical standardized uptake
value ratio [SUVr] greater than 1.42 with regional spread
function [RSF]–based partial volume correction [PVC])
[19,20].
To compare the two tracers in late-onset spectrum
populations, a cohort of 103 participants drawn from the
Knight Alzheimer’s Disease Research Center (ADRC)Table 1
Study cohorts
Variable
CAL* DIAN-TU
Noncarrier Carrier Noncarrier
N 15 22 50 (29 YC, 21 OC
Age (SD) years 39.3 (4.6) 54.5 (6.3) 43.3 (8.9)
Male (%) 7 (46.7) 14 (63.6) 26 (52.0)
APOE ε41 (%) 4 (26.7) 9 (40.9) 16 (32.0)
CDR . 0 (%) 0 (0.0) 16 (72.7) 3 (6.0)
Interval between scans (years) -
Abbreviations: ADRC, Alzheimer’s Disease Research Center; APOE, apolipop
Alzheimer’s Network Trial Unit; OC, old controls; PiB, Pittsburgh compound B;
*CAL (calibration data set) is a subset of DIAN-TU and is used for establishin
ySignificantly different (P , .0001 based on the Welch two-sample t-test).were enrolled in a crossover study to have both PiB and
florbetapir scans within a short time window (,1 month).
In addition, longitudinal PiB (N 5 54) and florbetapir
(N 5 26) data for participants from Knight ADRC with
positive baseline amyloid scans were included for further
comparison of these two tracers in measuring rate of amyloid
accumulation in a late-onset AD spectrum. Including
amyloid-positive participants only allows more accurate
assessment of the rate of amyloid accumulation, as PET
measurement in people with minimal amyloid burden is
mainly influenced by nonspecific binding and other factors
unrelated to amyloid. A summary of cohort characteristics
is presented in Table 1. For the longitudinal cohort, primary
analysis was based on two time points rather than the full
longitudinal data set because very few participants had
more than two florbetapir scans.
For all participants across the cohorts, dementia status was
assessed using the CDR and CDR sum-of-boxes (CDRSB)
score. The Mini–Mental State Examination (MMSE) [21]
was also performed to obtain an MMSE score. Each
participant’s apolipoprotein E (APOE) genotype was
determined using previously described methods [22]. For the
DIAN-TU cohort, EYO was calculated as the difference
between the participant’s age at evaluation and the age at which
parental cognitive decline began [2]. The ADAD mutation
status was determined using established methods [2]. Clinical
evaluators in the DIAN-TU study were blind to participant
mutation status.
2.1.1. Ethics statement
All assessment and imaging procedures were approved
by Washington University’s (WU’s) Human Research
Protection Office. Written informed consent was obtained
from all individuals or their authorized representatives.
Local institutional review boards also approved the image
collection and analysis at each non-WU study site.2.2. Imaging
For the DIAN-TU participants, all florbetapir PET scans
include data between 50 and 70 minutes after injection and
all PiB PET scans include data between 40 and 70 minutesADRC crossover ADRC longitudinal
Carrier PiB Florbetapir (AV45)
) 132 103 54 26
44.6 (10.1) 67.4 (8.9) 71.4 (7.0) 72.1 (6.8)
62 (47.0) 44 (42.7) 23 (42.6) 13 (50.0)
38 (28.8) 36 (35.0) 35 (64.8) 15 (57.7)
20 (15.2) 5 (4.9) 9 (16.7) 4 (18.2)
- - 2.2y 3.3y
rotein E; CDR, Clinical Dementia Rating; DIAN-TU, Dominantly Inherited
SD, standard deviation; YC, young controls (,45 yrs old).
g the florbetapir Centiloid conversions.
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was less than a month (range 0–28 days). For the sporadic AD
PiB-florbetapir crossover study, PiB PET includes data
between 30 and 60 minutes after injection and florbetapir
PET includes data between 50 and 70 minutes after injection.
The PiB-florbetapir scan interval was also less than a month
(range 1–18 days). For the longitudinal cohorts, same proto-
cols were used for PiB and florbetapir as the sporadic AD
crossover study. In addition to PET, 3D sagittal T1-weighted
images of the head were also acquired for each participant.2.3. Image analysis
PiB and florbetapir images were analyzed using our stan-
dard processing pipeline (PUP; https://github.com/ysu001/
PUP) [23,24]. Briefly, FreeSurfer (v5.3; Martinos Center for
Biomedical Imaging, Charlestown, Massachusetts, USA;
https://surfer.nmr.mgh.harvard.edu/fswiki) was used to
process T1-weighted magnetic resonance imaging data and
facilitate regional analysis of PET data. PUP processing
includes scanner resolution harmonization filter [25],
interframe motion correction, PET-to-magnetic resonance
registration, regional intensity extraction, RSF-based PVC
[23,26], and SUVr analysis using the cerebellar cortex as the
reference region. Although the brainstem/pons is commonly
used as the reference region for the investigation of ADAD
[2,5], we used the cerebellar cortex to be consistent among
cohorts, and also it has been shown recently that using the
cerebellar cortex generated similar results as brainstem
referencing in DIAN [27]. As the global index of amyloid
burden, a mean cortical SUVr was calculated based on a
selected set of cortical regions defined by FreeSurfer, that is,
frontal, parietal, temporal, and precuneus [24].
To facilitate between tracer comparison, PiB and
florbetapir SUVrs were both converted to the Centiloid
scale. The Centiloid conversion for PiB data was reported
previously [28]. For DIAN-TU data, the conversion
equations for 40- to 70-minute time window were used;
and for the crossover and longitudinal data set, the equations
for 30- to 60-minute time window were used
(see Supplementary Material for details). To establish the
Centiloid conversion equations for florbetapir PET
processed using PUP, we followed the recommended
level-2 calibration procedure [13]. The PiB PET data from
the calibration data set were analyzed using the Centiloid
pipeline to obtain PiB Centiloid SUVr according to Klunk
et al. [13]. Linear regression was then performed between
florbetapir mean cortical SUVrs and PiB Centiloid SUVrs
to obtain the florbetapir Centiloid conversion equations
using the level-2 calibration procedure [13]. These equations
were reported in Supplementary Material including the ones
using cerebellar cortex referencing used in our primary
analysis and equations derived for brainstem and white
matter referencing. All PUP-based mean cortical SUVrs
were then converted to the Centiloid scale using
corresponding equations. In subsequent analysis, we alwaysused the Centiloid values as the target variable, except where
we determined amyloid positivity based on SUVr thresholds
as discussed in our Supplementary Material.
2.4. Statistical analysis2.4.1. Cross-sectional analysis
Themean and standard deviation of the estimated amyloid
burden in the 29 youngADADmutation noncarriers from the
DIAN-TU cohort were used to assess the variability in the
amyloid burden measurement in Centiloids and define
amyloid positivity threshold using the specificity approach,
that is, 95th percentile of the amyloid burden measurements
for the young controls [29]. Multivariate linear models with
unstructured covariance matrix were used to compare the
means and interindividual variability of the two tracers. Simi-
larly,multivariate linearmodelswith unstructured covariance
matrix parameterized in terms of variances and correlations
were used to estimate and compare the strength of the
correlations between levels of amyloid burden and clinical/
cognitive outcomes by tracers. To test whether the two tracers
are equivalent in inter-individual variability and correlation
to other variables in the context of multivariate model, a
likelihood ratio test (test statistics approximately follow c2
distribution) was performed. A major advantage of using
the multivariate-model-based test is that other covariates
can be added into the model straightforwardly and be
adjusted for. One of the 132 mutation carrier DIAN-TU
participants was missing EYO data and excluded from this
correlation analysis. These analyses were done using Proc
Glimmix, SAS9.4 (SAS Institute Inc.,Cary,NC).Correlation
analysis was also performed for the cross-sectional sporadic
AD spectrum data to compare the two tracers.
2.4.2. Longitudinal analysis
For the longitudinal cohort of sporadic AD, baseline
amyloid positivity was determined based on previously es-
tablished criteria for PiB (mean cortical SUVr greater than
1.42 with RSF PVC) [19,20] and its equivalent florbetapir
cutoff of 1.19 (see SupplementaryMaterial for the derivation
of florbetapir cutoff). Multivariate linear mixed effects
models with random intercepts and random slopes were
used to estimate and compare the longitudinal change in am-
yloid burden for each tracer. Different covariance matrices
for the random effects and different residual variances
were assumed between tracers. These models can handle
missing, unbalanced, and unevenly spaced longitudinal
data and have been used in previous studies of AD [30].
These analyses were done using Proc Mixed, SAS 9.4.3. Results
3.1. Florbetapir Centiloid
Based on the calibration data set, the Centiloid
conversion equations for florbetapir SUVrs were generated
Y. Su et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 180-190184and listed in Supplementary Material. Our florbetapir
conversion equation (CL 5 163.6 x SUVr – 181.0)
(supp. Eq. 5) derived based on raw SUVrs without RSF
PVC was similar to the published equations from a recent
paper [16]. The difference is attributable to variation in
image acquisition protocols and quantification procedures.
Florbetapir mean cortical SUVrs strongly correlated with
PiB Centiloid SUVrs with (r 5 0.8861, P , .0001) or
without RSF PVC (r 5 0.8906, P , .0001, Supplementary
Fig. 2).3.2. DIAN-TU baseline analysis
The amyloid burden measured within the young mutation
noncarriers and the mutation carriers within the DIAN-TU
data set is reported in Table 2. Multivariate model analyses
showed that for the young control group, the mean amyloid
burden in the Centiloid scale was significantly different for
the two tracers when RSF PVC was used (t-test, df [degree
of freedom] 5 29, P , .0001), but not when correction
was not used (P 5 .10), whereas the variability was
significantly different with (SD 5 3.2 for PiB vs.
SD 5 5.4 for florbetapir, c2 test, df 5 1, P 5 .0006) and
without (SD 5 4.4 for PiB vs. SD 5 14.2 for florbetapir,
c2 test, df 5 1, P , .0001) RSF PVC (Table 2).
After conversion to the Centiloid scale, the amyloid
burden measured with each tracer was approximately in
the same range (0 to 200); however, because of the higher
variability, the specificity-based amyloid positivity
threshold (i.e., 95th percentile of young controls) was higher
in the Centiloid scale when florbetapir was used as the
imaging tracer (Table 2). For the DIAN-TU data, the
amyloid burden measurements were strongly correlated
between PiB- and florbetapir-based measurements with
(r 5 0.8433, P , .0001) and without (r 5 0.8428,
P , .0001) RSF PVC (Fig. 1), whereas the intraclass
correlation was significant with RSF PVC (0.5616,Table 2
Interindividual variability comparisons based on the DIAN-TU baseline data
Variable CL_PiB_SUVr CL_PiB_SUV
YC mean 21.2 0.3
YC SD 4.4 3.2
MC mean 65.6 66.3
MC SD 52.6 50.9
Specificity threshold (95%)
6.0 5.5
P values
Interindividual variability for YC
PiB versus AV45
RSF versus non-RSF .005
Comparison of YC mean
PiB versus AV45
RSF versus non-RSF .003
Abbreviations: ADAD, autosomal dominant Alzheimer’s disease; AV45, flor
Alzheimer’s Network Trial Unit; PiB, Pittsburgh compound B; RSF, regional spre
YC, young control participants (,45 years) without ADAD mutation. StatisticalP , .0001) but not without correction (0.3013, P 5 .17).
For the mutation carriers, the correlations between amyloid
burden and clinical variables such as MMSE, CDRSB, and
EYO were significantly different for the two tracers without
RSF PVC but were similar with correction (Table 3) based
on the likelihood ratio tests. It was also observed that
PiB-based measurements and quantification with RSF
PVC tend to have smaller P values and larger r-values
(Table 3). Scatter plots depicting the relationships between
amyloid burden and clinical variables are shown in Fig. 2.
When these relationships were assessed for APOE ε4
carriers only, similar (numerically slightly stronger) levels
of associations between amyloid burden and the clinical
variables were observed (Supplementary Table 1), although
we no longer observe a between-tracer difference.3.3. Sporadic AD crossover analysis
Amyloid burden measured using PiB and florbetapir
strongly correlated in the sporadic AD cohort similar to
the DIAN-TU cohort. The Pearson’s correlation for amyloid
burden in the Centiloid scale between the two tracers was
0.9071 (P , .0001) without and 0.9375 (P , .0001) with
RSF PVC (Fig. 3). The Centiloid conversion was able to
convert the amyloid burden measurements into a similar
dynamic range (approximately between 0 and 150 in the
Centiloid scale).3.4. Longitudinal analysis
Significant accumulation of amyloid was observed in the
longitudinal PiB cohort with (annual rate of change:
5.06 [0.40], P , .0001) or without PVC (annual rate of
change: 4.69 [0.37], P, .0001). The longitudinal florbetapir
data failed to show significant changes over time without
PVC (annual rate of change: 2.62 [2.36], P 5 .27)
but became significant when RSF PVC was performedr_RSF CL_Florbetapir_SUVr CL_Florbetapir_SUVr_RSF
2.7 4.1
14.2 5.4
65.2 63.0
54.4 44.3
26.1 12.9
,.0001 .0006
,.0001
.10 ,.0001
.53
betapir; MC, ADAD mutation carriers; DIAN-TU, Dominantly Inherited
ad function; SD, standard deviation; SUVr, standardized uptake value ratio;
significant P values (P , .05) are highlighted in bold.
Fig. 1. Comparison of amyloid burden measurements in the Centiloid scale using florbetapir without (A) and with (B) RSF PVC to PiB-based measurements in
the DIAN-TU mutation carriers. Abbreviations: DIAN-TU, Dominantly Inherited Alzheimer’s Network Trial Unit; PiB, Pittsburgh compound B; PVC, partial
volume correction; RSF, regional spread function; SUVr, standardized uptake value ratio.
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annualized rate of change in amyloid burden measure did
not differ by tracers with or without PVC (Fig. 4). Further
sensitivity analysis using all longitudinal data yielded almost
identical results (data not shown).3.5. Sample sizes required to detect the same reduction in
the annual rate of change by tracers
To demonstrate the effect of different tracers on the
sample size required to detect the same proportion (%) of
reduction in the annual rate of change, we used the rate of
change and related variances of the Centiloid scale with
RSF PVC to calculate the sample size. For ease of
demonstration, we conceptualized a treatment versus
placebo trial with 1:1 randomization ratio, 3-year duration
with annual assessments, 80% power, and 5% annual
dropout. The primary outcome was the annual rate of
change, and the primary analysis model was the linear mixed
effects model with random intercepts and random slopes.
The annual rates of change for the placebo group were those
estimated in Section 3.4: 5.06 for PiB and 3.62 for
florbetapir; for example, a 20% reduction for the treatment
group would lead to annual rates of change of 4.04 andTable 3
Pearson correlation between amyloid and clinical/cognitive outcomes by PET tra
Variable
Without RSF PVC
PiB PET, r (SE) AV45 PET, r (SE) P valu
EYO 0.529 (0.0630) 0.417 (0.0723) .0075
CDRSB 0.420 (0.0721) 0.299 (0.0797) .007
MMSE 20.359 (0.0762) 20.265 (0.0814) .0392
Abbreviations: AV45, florbetapir; CDRSB, CDR sum of boxes; EYO, estim
PET, positron emission tomography; PiB, Pittsburgh compound B; PVC, partial v2.90 for PiB and florbetapir, respectively. Table 4 presented
the sample size for a range of reductions in the rate of
change. A larger sample size would be required in a
hypothetical anti-amyloid trial if florbetapir is used as the
tracer. The discrepancy was attributed to the combination
of larger annual rate of change and smaller variance in the
PiB amyloid burden assessments compared with AV45
(florbetapir) assessments.4. Discussion
This study generated the linear conversion equations
from florbetapir SUVrs to the Centiloid scale following the
Centiloid Work Group guidelines [13] based on a data set
of 37 participants. Florbetapir-based amyloid burden
measurements strongly correlated with PiB-based
measurements (R2 . 0.70). We then performed direct
comparison of florbetapir against PiB-based amyloid
measurements in two independent cohorts. Based on the
DIAN-TU data set, which included 29 young controls who
did not have ADAD mutations and therefore are presumed
not to have amyloid in their brain, florbetapir imaging
demonstrated considerably higher measurement variabilities
than PiB imaging (Table 2). The Centiloid approach wascers
With RSF PVC
e PiB PET, r (SE) AV45 PET, r (SE) P value
0.553 (0.0607) 0.503 (0.0654) .218
0.453 (0.0695) 0.388 (0.0744) .134
20.387 (0.0744) 20.336 (0.0776) .259
ated years to symptom onset; MMSE, Mini–Mental State Examination;
olume correction; RSF, regional spread function; SE, standard error.
Fig. 2. Association between amyloid burden measurements and clinical variables. (A) Florbetapir SUVr versus MMSE; (B) PiB SUVr versus MMSE; (C) Flor-
betapir SUVr versus CDRSB; (D) PiB SUVr versus CDRSB; (E) Florbetapir SUVr versus EYO; (F) PiB SUVr versus EYO. All SUVr measurements have been
converted to the Centiloid scale. Abbreviations: CDRSB, CDR sum of boxes; EYO, estimated years to symptom onset; MMSE, Mini–Mental State Examina-
tion; PET, positron emission tomography; PiB, Pittsburgh compound B; SUVr, standardized uptake value ratio.
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Fig. 3. Comparison of amyloid burden measurements in the Centiloid scale using florbetapir without (A) and with (B) RSF PVC to PiB-based measurements in
the sporadic AD crossover cohort. Abbreviations: AD, Alzheimer’s disease; PiB, Pittsburgh compound B; PVC, partial volume correction; RSF, regional spread
function; SUVr, standardized uptake value ratio.
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the two tracers into a similar dynamic range. We did not
observe statistically significant differences in the estimated
average rate of amyloid accumulation using the two tracers
in the longitudinal analysis, although the difference in
measurement variability led to difference in statistical power
in detecting longitudinal change and sample size needed in
hypothetical clinical trials. Note that, although both PiB
and florbetapir data were converted to Centiloid units for
the purpose of this comparison so that the dynamic range
of both tracers would be in a similar range, all results would
have been quantitatively and statistically equivalent without
this conversion because it is a simple linear transformation
of the data.Pittsburgh Compound B (PiB) Florbetapir (AV45)
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two tracers. (B) Rate of change as a function of baseline amyloid burden. No dif
(P 5 .555).The cross-sectional comparison between PiB and
florbetapir in this study was made based on a crossover
design where the two scans were performed within 1 month
in the same participants in both an ADAD and a sporadic AD
cohort. Previously, Laudau et al. [31] compared these two
tracers using florbetapir data collected approximately
1.5 years after PiB imaging and found a correlation between
0.86 and 0.95 depending on the quantification method
used. More recently, Navitsky et al. [16] reported a
florbetapir-to-PiB SUVr correlation of approximately 0.95.
These results are in agreement with ours. The Centiloid
conversion and comparison to PiB has been reported for
two other 18F-tracers, that is, [18F]-NAV4694 [14] and
[18F]-florbetaben [15]. An intertracer correlation of−30
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betapir in the longitudinal cohort. (A) Box plot of rate measurements for the
ference was observed between the rate measurements from the two tracers
Table 4
Sample size for a 2-year trial by tracers (using RSF-PVC-based amyloid
burden measurements)
Tracer
Reduction in the annual rate of change
20% less 40% less 60% less 80% less
AV45 2156 539 240 135
PiB 305 77 34 20
Abbreviations: AV45, florbetapir; PiB, Pittsburgh compound B;
PVC, partial volume correction; RSF, regional spread function.
Y. Su et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 180-190188R2 5 0.99 was observed between PiB and [18F]-NAV4694,
and R2 5 0.96 was observed between PiB and
[18F]-florbetaben. The variance of amyloid burden
measurements in young controls was SD 5 3.7 for
[18F]-NAV4694 and SD 5 6.81 for [18F]-florbetaben
[14,15]. Recently, Navitsky et al. [16] reported an
SD 5 12.07 for florbetapir, and here, we observed an
SD 5 14.2 for the raw florbetapir SUVr-derived Centiloid
measurements; however, when the RSF PVC technique
was used in the quantification procedure, the variance was
substantially reduced (SD 5 5.4). This suggests that the
variability in a pathologically free cohort may primarily be
related to nonspecific uptake in the white matter, and PVC
can reduce this effect. In this study, we used the cerebellar
cortex as the reference region for quantification, whereas
several groups have suggested that the use or inclusion of
white matter as the reference region lead to lower variability
and better statistical power in longitudinal studies [32,33].
Further investigation is warranted, especially considering
the reports of myelin binding of amyloid PET tracers
[34,35] and the age-related change in white matter amyloid
PET signal [36].
In our previous work [28], we reported that the thresholds
for amyloid positivity are dependent on the criteria used for
definition and the quantification method, even after
Centiloid conversion. In a multicenter European study
[37], a 95% specificity-based SUVr threshold was
transformed into the Centiloid scale and resulted in a cutoff
of 34, which differed considerably from our previous
work and the present study. Recently, postmortem
neuropathology–driven thresholds were also reported [38];
however, depending on the metrics used for pathology
evaluation, it also resulted in different thresholds. The
current work further strengthens the observation that
amyloid positivity cutoffs are sensitive to amyloid tracer,
quantification method, and the underlying cohort used to
derive the cutoff. A universal and physiologically/
pathologically meaningful threshold remains a challenge
and requires further investigation.
One limitation of this study is that the Centiloid
conversion for florbetapir is established based on an
ADAD cohort, which may have different patterns of amyloid
pathology than the sporadic AD population. Although we
have crossover data in the sporadic AD cohort, the PiB
imaging protocol in that cohort only acquires data up to60 minutes after injection and does not satisfy the
50–70 minutes requirement put forward by the Centiloid
Working Group [13]. Although the optimal Centiloid
conversion strategy for florbetapir-derived amyloid burden
measurements remains to be determined with additional
data and further research, our comparison between PiB
and florbetapir is still valid as the Centiloid conversion is
simply a linear transformation, which does not alter the
statistical distribution of the underlying data. We do not
expect the observed signal-to-noise properties to change
with a different Centiloid conversion strategy. Our
longitudinal comparison is limited by the fact that the PiB
and florbetapir data were collected on two similar but
separate cohorts; therefore, it may not have the power to
detect small differences between the longitudinal
performances of the two tracers. Also, the large differences
in estimated sample size in hypothetical trials should also be
interpreted with caution as the underlying mean and
standard deviation data are not derived from the same
population. Future studies are necessary to further compare
different amyloid tracers in longitudinal studies.5. Conclusion
Florbetapir-based amyloid measurements had higher
variability, which may relate to its white matter nonspecific
uptake and lower dynamic range before Centiloid
transformation. The difference in variability also resulted
in large differences in the 95% specificity-based amyloid
positivity threshold and differences in ability to detect subtle
amyloid burden. Further study is necessary to characterize
tracer performance in longitudinal studies.Acknowledgments
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1. Systematic review: The literature was reviewed using
PubMed to identify recent publications on the
comparison of different amyloid positron emission
tomographic (PET) imaging tracers and the
application of the Centiloid approach for
harmonization of amyloid burden measurements.
2. Interpretation: This work thoroughly compares two
widely used amyloid PET imaging tracers in both
autosomal dominant Alzheimer’s disease and late-
onset Alzheimer’s disease spectrum cohorts to
examine their sensitivity to amyloid burden and its
change over time. The comparison also adopted the
Centiloid approach to bring different amyloid PET
measurements into a common scale.
3. Future directions: Significant differences in sensi-
tivity to amyloid burden and its longitudinal change
were observed for the two tracers even after convert-
ing to the Centiloid scale. This resulted in substantial
differences in sample sizes needed for hypothetical
antiamyloid trials. Further longitudinal study is
needed to verify this finding and compare different
amyloid PET tracers.References
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